Location: Home
  • search
  • go
  • Relate News
  • 7/1/2025China Launches New Tax Incentives to Boost Foreign Companies' Reinvest...
  • 7/1/2025China's STAR Market Approves Heyuan Biotech's IPO
  • 7/1/2025Jinhua Conba and EVA Forge Strategic Partnership to Strengthen China-M...
  • 7/1/2025Record China Pharma Monopoly Fine Sends Strong Deterrent Signal, Exper...
  • 6/30/2025BlissBio Advances Toward IPO with Focus on Next-Generation ADC Therapi...
  • 6/30/2025CTTQ's Anlotinib Wins Approval in China for First-Line Treatment of Ad...
  • 6/30/2025Cutia's Topical Finasteride Spray CU‑40102 Approved in China for Hair...
  • 6/30/2025Pfizer China's Emblaveo Cleared by NMPA for Tough Gram‑Negative Infec...
  • 6/30/2025Conjupro Files USPTO Challenge on Ascletis' U.S. Patent for GLP‑1R Ag...
  • 6/30/2025QL Biopharma's Dual GLP‑1/FGF21 Agonist ZT‑003 Gains IND Nod in U.S....
  • 6/30/2025GenFleet IPO Highlights Promising RAS-Targeted Drug Pipeline
  • 6/30/2025China Medical System to Pursue Secondary Listing on Singapore Exchange
  • 6/30/2025China's Pharma Market Faces Mixed Performance in Q1 2025 Amid Shifting...
  • 6/30/2025China's Draft National Medical Security Law: Seven Key Highlights Sign...
  • 6/30/2025CDE Reopens Public Consultation on Revised Technical Guidelines for Co...
  • 6/28/2025I-Mab Unveils Encouraging Givastomig Results in First-Line Gastric Can...
  • 6/28/2025Innovent Wins Landmark China Approval for Obesity Drug Challenging Nov...
  • 6/28/2025China Raises Per Capita Public Health Funding to Support Seniors, Chil...
  • 6/28/2025China Releases Draft Medical Security Law for Public Comment
  • 6/28/2025Recent Official and Executive Moves
  • 6/27/2025CARsgen Submits NDA for Satri‑cel, Poised to Be First CAR‑T for Soli...
  • 6/27/2025Bayer and Tsinghua University Extend 16-Year Partnership to Advance Gl...
  • 6/27/2025Mabwell Strikes Major $596M Deal with Calico to Advance Anti-Aging IL-...
  • 6/27/2025Theravance Partner Viatris Lands NMPA Approval for YUPELRI, Unlocking ...
  • 6/27/2025Arbutus and Qilu End Partnership as Arbutus Regains Full Rights to Imd...
  • 6/27/2025Fresh Antitrust Guidelines to Address Pharmaceutical Monopoly Issues i...
  • 6/27/2025Analyzing Key Trends in China's Patent-Linkage System and Their Impact...
  • 6/26/2025Immvira Advances Toward HKSE Listing with Focus on Oncolytic Virus The...
  • 6/26/2025BrightGene Seeks Partner for Obesity Drug Aimed at Surpassing Zepbound
  • 6/26/2025Vor Bio Secures ex-China Global Rights to RemeGen's Telitacicept
  • Page:24/797 Total number of articles:23898: [First][<<] [22] [23] [24] [25] [26] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group